VTRS Viatris Inc. Common Stock PHARMACEUTICAL PREPARATIONS Best Pharmaceutical Stocks 2026 →

Viatris (VTRS) Stock: Buy, Sell, or Hold?

$20.67
-0.39 (-1.85%) ▼
5d: +8.96% 30d: +18.52% 90d: +27.36%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (27%)
Quality Score
45/100
Position
EXTENDED
30-Day Fair Range
$17.61 – $19.73
Position: EXTENDED
Forward P/E & Valuation
7.5x STRETCHED
vs 5.9x historical avg
Wall Street Target
$21.00
+1.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$18.64 / $21.20
Trend: Strong Uptrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: VTRS shows conflicting indicators. Wait for confirmation before entering.
Smart Money Distribution

Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →

Signal fired Nov 5, 2026 at $19.05 · last confirmed Nov 10, 2026

Strength: 6.6/10

Get Alerted When VTRS Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$20.81
Based on 5.1% avg growth
INTRINSIC VALUE TODAY
$12.92
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.9x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: VTRS is currently trading at $20.67, which is considered extended relative to its 30-day fair value range of $17.61 to $19.73. From a valuation perspective, the stock is trading at a premium (Forward PE: 7.5) compared to its historical average (5.9). At these levels, the market is pricing in 8.4% annual earnings growth.

Technical Outlook: Technically, VTRS is in a strong uptrend. The price is approaching resistance at $21.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: VTRS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $17.61 - $19.73
Company Quality Score 45/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 27.1%

Trading Range & Key Levels

30-Day Trading Range $17.61 - $19.73
Current vs Trading Range EXTENDED
Support Level $18.64
Resistance Level $21.20
Current Trend Strong Uptrend
Technical data as of Nov 12, 2026

Protect Your Profits

Holding VTRS? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

Quantitative Signal Breakdown

  • BEARISH: Price extended above range
  • BEARISH: Weak technical setup (15/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($21.00)
  • BULLISH: Expecting earnings turnaround to 8.4% growth with -0.3% revenue growth
  • WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 7.51
Wall Street Target $21.00 (+1.6%)
Revenue Growth (YoY) -0.3%
Earnings Growth (YoY) -70.6%
Profit Margin -4.1%
Valuation Premium vs History +8.4% premium
PE vs Historical 7.5 vs 5.9 STRETCHED
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +8.4% (market-implied from PE analysis)
1-Year Target $22.41 (+8%)
2-Year Target $24.29 (+18%)
3-Year Target $26.33 (+27%)
3-Yr Target (if PE normalizes) (PE: 8→6) PE COMPRESSION $20.67 (0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 19.9, Growth: 6.2%) $65.36 (+216%)
Base: (SPY PE: 7.5, Growth: 6.2%) $24.73 (+20%)
Bear: (PE: 5.9, Growth: 6.2%) $19.42 (-6%)
Share VTRS Analysis

Share this live VTRS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

Reddit StockTwits X / Twitter
bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (VTRS)

Bullish 2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary: Lexicon Pharmaceuticals ($VTRS) is set to present at the Jefferies Global Healthcare Conference in London on November 18, providing an opportunity for investors to gain insights into the company.
Key Retail Themes: Upcoming event Company presentation
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 3:58 AM ET
Data refreshes hourly during market hours. Next update: 4:58 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
See Full Scanner Results »
Technical Signals Check

Is VTRS showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for VTRS.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NBIX
Neurocrine Biosciences I… 		STRONG BUY
29 analysts 		$208 23 SELL
ALKS
Alkermes Plc 		STRONG BUY
20 analysts 		$58 41 HOLD
AQST
Aquestive Therapeutics I… 		STRONG BUY
9 analysts 		$9 60 BUY
TEVA
Teva Pharma Industries L… 		STRONG BUY
15 analysts 		$49 36 SELL
HROW
Harrow Health Inc 		STRONG BUY
9 analysts 		$63 51 HOLD
NBIX Neurocrine Biosci…
23 SELL
ALKS Alkermes Plc
41 HOLD
AQST Aquestive Therape…
60 BUY
TEVA Teva Pharma Indus…
36 SELL
HROW Harrow Health Inc
51 HOLD

Advanced VTRS Option Strategies

Professional options setups generated by AI based on today's VTRS price and gamma walls.

Iron Condor Bull Call Bear Put Collar

Explore More Analysis & Live Quant Tools

Part A: Deep-Dive VTRS Research Pages
VTRS Technical Chart VTRS Price Prediction VTRS Intrinsic Value DCF VTRS Earnings Date VTRS Investment Advisor VTRS Fair Price Analyzer VTRS Options Chain VTRS Options Advisor VTRS Options Analysis VTRS Competitors
Part B: Tradestie Flagship Market Scanners
Today's Best Signals (VTRS) Sector Rotation Monitor AI Supply Chain Money Flow Gamma Squeeze (GEX) Scanner Undervalued Stocks Scanner Insider Cluster Buying Reddit & WSB Sentiment Tracker Backtested Stock Scanner
Compare VTRS with Peers
VTRS vs OGN
Which one to buy?
VTRS vs GEHC
Which one to buy?
VTRS vs CTVA
Which one to buy?
VTRS vs LUMN
Which one to buy?
VTRS vs WAB
Which one to buy?
ABEO vs VTRS
HIMS vs VTRS
VTRS vs PFE
VTRS vs RGC
RDY vs VTRS
OVID vs VTRS
NBIX vs VTRS
Winner: VTRS
TAK vs VTRS
Winner: Tie
PTCT vs VTRS
VTRS vs CTVA
Winner: CTVA
Create New Comparison View All Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals